Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders was 200 million RMB, which is a decrease of 10% compared to the previous year[15]. - The company's operating revenue for 2022 was ¥157.71 million, a decrease of 51.09% compared to ¥322.43 million in 2021[22]. - The net profit attributable to shareholders for 2022 was ¥4.20 million, down 93.09% from ¥60.84 million in 2021[22]. - The company reported a quarterly revenue of ¥51.24 million in Q4 2022, showing a significant increase compared to previous quarters[27]. - The net profit attributable to shareholders in Q4 2022 was ¥11.05 million, marking a recovery from losses in earlier quarters[27]. - The company achieved a total operating revenue of ¥157,707,909.65, a decrease of 51.09% compared to the previous year[60]. - The net profit attributable to the parent company was ¥4,201,241.96, down 93.09% year-on-year[60]. - Revenue from military products was ¥30,720,182.34, down 53.54% from ¥66,126,629.56 in 2021, with a gross margin of 49.23%[69]. - Revenue from agricultural product processing and sales increased by 22.70% to ¥119,486,289.06, with a gross margin of 12.92%[69]. User Engagement and Market Expansion - User data showed an increase in active users by 25%, reaching a total of 5 million users by the end of 2022[15]. - The company plans to expand its market presence in three new provinces, aiming for a 30% increase in market share by 2024[15]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[98]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion, driven by new product launches and market expansion[98]. Research and Development - The company has allocated 50 million RMB for research and development in new technologies for urban infrastructure[15]. - Research and development expenses amounted to ¥3,582,789.59, with capitalized R&D costs of ¥2,584,556.76 primarily from the subsidiary[62]. - R&D investment accounted for 2.27% of operating revenue in 2022, up from 1.66% in 2021, an increase of 0.61%[79]. - The company is committed to independent research and development to maintain its leading technological position in the industry[43]. - The company is focused on developing new products in the fields of biological feed and organic fertilizers, aiming to enhance its market offerings[99]. Strategic Investments and Acquisitions - The company is exploring potential mergers and acquisitions to enhance its service offerings and market reach[15]. - A strategic acquisition was completed, adding 50 million in annual revenue and expanding the company's product portfolio[98]. - The company acquired a 51.01% stake in a biomedical company for ¥21,000,000, enhancing its presence in the medical equipment sector[92]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its portfolio[92]. - The company plans to establish a holding subsidiary as part of its investment strategy, approved on November 21, 2022[163]. Operational Efficiency and Cost Management - Operating margin improved to 20%, up from 18% in the previous year, reflecting better cost management and operational efficiency[98]. - The company has outlined future growth strategies that include enhancing operational efficiency and expanding into new markets[92]. - The company plans to enhance its operational strategy by expanding horizontally and vertically while improving internal controls[44]. Agricultural Focus - The agricultural sector is expected to grow, with the company focusing on modern agricultural practices and achieving a record grain output of over 140 million tons in 2022[34]. - The company has established a wholly-owned subsidiary in Baishan City to develop agricultural business, aiming to expand its product offerings beyond rice to include local agricultural products[47]. - The company is focused on expanding its agricultural production services and management activities[95]. - The company is advancing its astaxanthin project in Baishan City, aiming for rapid construction and mass production, with a focus on developing a complete astaxanthin industry chain[113]. Governance and Management - The company has established independent organizational structures that function separately from the controlling shareholder[130]. - The company has a diverse board of directors, including independent directors, ensuring governance and oversight[135]. - The company is committed to transparency and has disclosed all relevant information regarding board member changes and shareholder meetings[136]. - The company has undergone significant management changes, with multiple appointments and resignations in early 2022, indicating a potential shift in strategic direction[137]. - The company is focused on strengthening its governance structure through the appointment of qualified independent directors[146]. Environmental Responsibility - The company and its subsidiaries are not classified as key pollutant discharge units by environmental protection authorities[199]. - There were no administrative penalties due to environmental issues during the reporting period[199]. - The company has implemented measures to reduce carbon emissions, although specific details were not disclosed[200].

万方城镇投资发展股份有限公司 2022 年第三季度报告 证券代码：000638 证券简称：万方发展 公告编号：2022-066 万方城镇投资发展股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 1 / 12 万方城镇投资发展股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 48,388,336.44 | -36.97% | 106,468,756 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥58,080,420.49, a decrease of 26.32% compared to ¥78,825,016.48 in the same period last year[20]. - The net profit attributable to shareholders was a loss of ¥7,497,597.76, representing a decline of 172.64% from a profit of ¥10,321,115.30 in the previous year[20]. - The net cash flow from operating activities was negative at ¥53,755,985.53, which is a 40.74% increase in cash outflow compared to ¥38,195,209.85 in the same period last year[20]. - The basic and diluted earnings per share were both -¥0.0242, down 172.46% from ¥0.0334 in the previous year[20]. - The company's revenue for the reporting period was ¥58,080,420.49, a decrease of 26.32% compared to ¥78,825,016.48 in the same period last year, primarily due to severe domestic pandemic conditions[51]. - The company reported a significant decrease in revenue from military products, down 78.96% to ¥5,560,282.58, compared to ¥26,433,033.56 in the previous year[54]. - Revenue from grain processing and sales surged by 253.33% to ¥48,943,566.96, up from ¥13,852,158.89 year-on-year[54]. - The company's total operating revenue for the first half of 2022 was ¥58,080,420.49, a decrease of 26.32% compared to ¥78,825,016.48 in the same period last year[54]. - The net profit for the first half of 2022 was a loss of ¥8,162,077.01, compared to a profit of ¥10,766,780.60 in the first half of 2021[193]. - The total comprehensive income for the first half of 2022 was a loss of ¥8,264,461.79, contrasting with a profit of ¥10,766,780.60 in the first half of 2021[193]. Assets and Liabilities - The total assets at the end of the reporting period were ¥493,037,754.07, a decrease of 12.23% from ¥561,721,695.91 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 9.84% to ¥157,861,192.92 from ¥175,080,444.32 at the end of the previous year[20]. - The company's cash and cash equivalents decreased significantly by 354.80% to -¥96,002,024.72 from -¥21,108,730.70 in the previous year[52]. - The company's total assets included cash of ¥26,944,772.34, which accounted for 5.47% of total assets, down from 21.89% the previous year[60]. - The company's total assets amount to 16,244.54 million, with net assets of 7,285.58 million[76]. - The company's total liabilities decreased to CNY 275,696,615.54 from CNY 320,842,975.67, a decline of around 14.0%[185]. - The owner's equity decreased to CNY 217,341,138.53 from CNY 240,878,720.24, representing a decrease of about 9.8%[185]. Operational Challenges and Strategies - The company faced significant operational challenges leading to a negative return on equity of -4.33%, down from 9.02% in the previous year[20]. - The company has outlined risks and countermeasures in its management discussion, emphasizing the need for strategic adjustments in response to market conditions[5]. - In the first half of 2022, the company focused on optimizing asset allocation and improving operational efficiency amid ongoing domestic pandemic impacts and economic pressures[28]. - The company’s military and agricultural businesses have not yet stabilized, affecting its operational resilience[83]. - The company faced risks due to macroeconomic fluctuations and COVID-19 policies, which disrupted supply chains and impacted financial performance[77]. Research and Development - The R&D team is led by Professor Xing Dawei, who has extensive experience in new materials development and has participated in several national research projects[41]. - The company has applied for multiple patents related to new material preparation technologies, with 3 invention patents and 1 utility model already authorized[45]. - The company aims to enhance its R&D capabilities and expand its product offerings in the biopharmaceutical sector, striving to become a comprehensive entity in vaccine development and production[49]. - The company is focusing on the agricultural sector through its subsidiary, WanFang MaiJie, which aims to integrate high-tech elements into rural logistics to enhance efficiency and support local economic development[47]. Investments and Subsidiaries - The company has completed an investment of 21 million in Wanfang Bio, acquiring a 51.01% stake[65]. - The company has established a new agricultural technology venture with an investment of 10 million, holding a 100% stake[65]. - The company is involved in various sectors including medical research, health consulting, and sales of medical devices[65]. - The company’s subsidiary, Wanfang Bai'ao, signed a framework agreement to acquire at least 15% of the equity of Yadong Biological (Anguo) for an initial payment of RMB 30 million, with adjustments made to the counterparties involved in the transaction[158]. - The company invested in 24% equity of Weihai Dongxun Biotechnology Co., which specializes in the research, manufacturing, and sales of natural astaxanthin, a product used as an additive in aquaculture feed[159]. Shareholder and Governance Commitments - The company emphasizes the protection of shareholder and creditor rights by ensuring accurate and complete information disclosure[98]. - The company has committed to maintaining the independence of its operations, ensuring that its assets are fully under its control and not misused by other entities[115]. - The company guarantees that its financial department operates independently, with a separate accounting system and bank accounts, ensuring no shared financial resources with other controlled entities[115]. - The company has committed to not using the assets of the listed company to provide guarantees for debts of its controlled enterprises[123]. - The company has pledged to maintain independent operations, ensuring that its assets, personnel, and qualifications are not interfered with by its controlling entities[123]. Financial Support and Future Plans - Huide Industrial committed to provide no less than 200 million CNY in funding support to improve the financial condition and liquidity of the listed company and its subsidiaries[105]. - The company plans to provide at least 58 million CNY for agricultural subsidiary Wan Fang Mai Jie for agricultural product processing and sales, and grain storage[107]. - The company plans to propose a private placement within 6 months after resuming listing, aiming to inject all relevant operational assets in real estate development to enhance sustainable profitability[127]. - The controlling shareholder, Huide Industrial, has delayed the implementation of its financial support plan, which includes a commitment to sign a debt transfer cooperation agreement by June 30, 2022, and to release RMB 57 million in funds by April 30, 2022, based on the company's operational needs[157].

2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经过审计 证券代码：000638 证券简称：*ST 万方 公告编号：2022-038 万方城镇投资发展股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 □ 是 √ 否 万方城镇投资发展股份有限公司 2022 年第一季度报告全文 万方城镇投资发展股份有限公司 2022 年第一季度报告全文 单位：元 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 28,853,677.06 | 30,359,764.25 | -4.96% | | 归属于上市公司股东的净利润（元） | -4,185,0 ...

Financial Performance - The company's operating revenue for 2021 was CNY 322,434,250.75, representing a 190.50% increase compared to CNY 110,993,349.65 in 2020[22] - The net profit attributable to shareholders for 2021 was CNY 60,841,368.94, a significant increase of 456.73% from a loss of CNY 17,055,247.54 in 2020[22] - The basic earnings per share for 2021 was CNY 0.20, compared to a loss of CNY 0.06 per share in 2020, marking a 433.33% improvement[22] - The diluted earnings per share for 2021 was CNY 0.19, compared to a loss of CNY 0.06 in 2020, reflecting a 416.67% increase[22] - The company achieved total revenue of ¥322,434,250.75 in 2021, representing a year-on-year growth of 190.50%[62] - Net profit attributable to the parent company reached ¥60,841,368.94, a significant increase of 456.73% compared to the previous year[62] - The revenue from medical software and hardware sales accounted for 47.19% of total revenue, amounting to ¥152,140,935.37, with a year-on-year growth of 66.92%[69] - The grain processing and sales segment generated revenue of ¥98,438,445.12, representing 30.53% of total revenue and a remarkable growth of 437.73% year-on-year[62] Cash Flow and Financial Position - The net cash flow from operating activities for 2021 was negative CNY 52,777,081.12, worsening from negative CNY 1,739,421.80 in 2020[22] - The company reported a total operating cost of ¥228,149,317.35, which increased by 184.56% compared to the previous year[63] - The net cash flow from operating activities was -¥52,777,081.12, indicating challenges in operational cash generation[65] - The company generated a net cash flow of ¥65,947,026.35 from investing activities, mainly from the disposal of subsidiary equity[66] - The financing activities resulted in a net cash flow of ¥83,241,933.12, primarily from loans and investments in subsidiaries[67] - The total cash and cash equivalents increased by 96,411,878.55 CNY, marking a 759.41% rise compared to the previous year[85] - The company's monetary funds accounted for 21.89% of total assets, up from 5.98% in the previous year, indicating a significant increase in liquidity[93] Strategic Focus and Business Development - The company plans not to distribute cash dividends or issue bonus shares[7] - The company aims to leverage opportunities in the military trade market, which is expected to grow and enhance domestic military industry development[34] - The biopharmaceutical sector is a key focus for the company, driven by increasing health security demands due to population growth and aging trends in China[37] - The company aims to enhance its competitive edge through innovation in vaccine development, with a focus on integrating and consolidating the vaccine industry[38] - The company is actively divesting non-strategic assets to optimize its asset allocation and improve overall competitiveness[39] - The military and agricultural sectors are identified as new growth points for the company, contributing to its diversified business strategy[39] - The company plans to focus on military communication, agriculture, and biotechnology sectors, optimizing its business structure through asset sales[105] Governance and Compliance - The company emphasizes the importance of risk awareness regarding future plans and strategies, as outlined in the management discussion section[6] - The company has established a transparent performance evaluation system for directors, supervisors, and managers, linking their compensation to business performance[133] - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[131] - The company maintains independent operations from its controlling shareholder, with separate personnel, assets, and financial management systems[137] - The company has implemented a rigorous information disclosure process, ensuring timely and accurate communication with shareholders[136] - The company has established various specialized committees within the board, including an audit committee and a nomination committee, to enhance governance[131] - The company is committed to improving its internal control system and governance structure to ensure high-quality development[114] Research and Development - Research and development expenses amounted to ¥10,748,324.02, with capitalized R&D costs of ¥5,774,849.28 primarily from subsidiaries[64] - The company has developed several new products, including gradient AL-SI50 aluminum-silicon alloy composite materials, which have been patented and are expected to enhance core competitiveness[80] - The company is continuously improving its R&D project management mechanism to align R&D directions with market trends and manage R&D expenses effectively[122] - The company plans to enhance its R&D capabilities and expand its product offerings in the biopharmaceutical sector, focusing on vaccines and recombinant protein drugs[60] Market Expansion and User Engagement - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[154] - A strategic acquisition of a local competitor is anticipated to enhance the company's service offerings and increase market penetration[154] - The company plans to implement a new customer engagement strategy aimed at improving user retention by 15%[154] - Operational efficiency initiatives are projected to reduce costs by 5%, enhancing overall profitability[154] Employee and Management Structure - The company has a total of 139 employees, with 43 in production, 6 in sales, 45 in technology, 18 in finance, and 27 in administration[181] - The company’s remuneration policy is based on budget management and includes various salary adjustment mechanisms to ensure competitiveness and fairness[182] - The company has implemented a stock option incentive plan in 2021, granting 7.7 million stock options to 10 initial recipients, aimed at stabilizing the management team and motivating key personnel[182][183] - The company’s management team has undergone significant changes, including the appointment of new independent directors and a financial director[147] Investor Relations and Communication - The company has been actively engaging with investors regarding restructuring and capital increase activities throughout 2021[124] - There have been multiple inquiries from investors about the risk of delisting, indicating concerns about the company's stock performance[125] - The company has received questions regarding its performance forecasts and restructuring progress, reflecting investor interest in future growth prospects[126] - The company is enhancing investor relations through transparent communication and engagement with stakeholders[116]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥53,489,704.89, a decrease of 32.14% compared to ¥78,825,016.48 in the same period last year[22]. - The net profit attributable to shareholders was a loss of ¥9,475,769.56, representing a decline of 191.81% from a profit of ¥10,321,115.30 in the previous year[22]. - The net cash flow from operating activities was negative at ¥53,755,985.53, a decrease of 40.74% compared to ¥38,195,209.85 in the same period last year[22]. - The total assets at the end of the reporting period were ¥493,037,754.07, down 12.02% from ¥560,427,933.31 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 10.84% to ¥157,861,192.92 from ¥177,058,616.12 at the end of the previous year[22]. - The basic earnings per share were -¥0.0306, a decline of 191.62% from ¥0.0334 in the same period last year[22]. - The weighted average return on equity was -5.50%, down 14.52% from 9.02% in the previous year[22]. - The company reported a revenue of ¥53,489,704.89 for the current period, a decrease of 32.14% compared to ¥78,825,016.48 in the same period last year, primarily due to severe domestic pandemic conditions[52]. - The company reported a total revenue of 4,435.29 million with a net profit of -206.92 million for its subsidiary, Maijie Agriculture[80]. - The company faced significant challenges due to the COVID-19 pandemic, impacting supply chains and overall economic conditions, which are expected to have a prolonged negative effect on financial performance[81]. Investment and Acquisitions - The total investment amount for the reporting period was ¥43,000,000, a decrease of 40.28% compared to ¥72,000,000 in the same period last year[65]. - The company acquired a 51.01% stake in WanFang BaiAo Biotechnology Co., Ltd. for ¥21,000,000, with the transaction completed on January 26, 2022[68]. - A new investment of ¥10,000,000 was made in WanFang Agricultural Technology Co., Ltd., representing a 100% ownership stake, established in March 2022[68]. - The company reported a total investment amount of 43,000,000.00 CNY, with a 24.00% equity stake in Weihai Dongxun Technology Co., Ltd. as of the reporting date[70]. - The company invested in 24% equity of Weihai Dongxun Biotechnology Co., which specializes in the research, manufacturing, and sales of natural astaxanthin, a product with significant technical barriers due to its complex biological synthesis process[164]. - The company signed a supplemental agreement to acquire at least 15% equity of Beijing Yadong Biopharmaceutical (Anguo) Co., with an initial payment of RMB 30 million, following changes in the equity structure of the target company[163]. Operational Focus and Strategy - In the first half of 2022, the company focused on optimizing asset allocation and improving its overall competitiveness amid ongoing domestic pandemic impacts and economic pressures[30]. - The company’s main business segments include military industry, agriculture, and biological products[31]. - The military business segment has made significant progress in developing new materials for military applications, including high-silicon aluminum alloys and gradient silicon-aluminum composite materials[32]. - The agricultural subsidiary, WanFang MaiJie, aims to become a key grain storage base and is working towards becoming a key leading enterprise in Jilin Province[38]. - The company is expanding its agricultural product offerings under the "Chongmi" brand, which has gained market recognition for its quality[41]. - The biological products subsidiary, WanFang BaiAo, is leading the market entry of two recombinant hepatitis B vaccines and is working on acquiring a stake in Yadong Biotechnology[42]. - The company aims to enhance its R&D capabilities and expand its product offerings in the bioproducts sector, aspiring to become a comprehensive bioproduct company[51]. Risk Management - The company faces operational risks and has outlined corresponding measures in its risk management section[5]. - The company has identified risks related to market competition, particularly in the development of gradient silicon-aluminum composite materials and other advanced materials, and plans to enhance product development and market expansion efforts[82]. - The company is taking measures to improve disaster resilience in agriculture to mitigate risks associated with natural disasters[84]. - The company is expanding into new business areas, which presents challenges in talent acquisition and market entry, and is implementing strategies to optimize operational capabilities[85]. Corporate Governance and Compliance - The company emphasizes the protection of shareholder and creditor rights by adhering to relevant laws and regulations for accurate information disclosure[102]. - The company has committed to ensuring that its assets are independently controlled and not used for the debts of the parent company or its controlled entities[113]. - The company has established a commitment to reduce and standardize related party transactions, ensuring that no related party transactions exist as of the commitment date[115]. - The company guarantees that its financial department operates independently, with a complete and independent financial accounting system[113]. - The company has committed to maintaining an independent operational capability, with the necessary assets, personnel, qualifications, and abilities to operate independently in the market[115]. - The company has established a long-term commitment to comply with the relevant regulations of the China Securities Regulatory Commission regarding the independence of listed companies[115]. Shareholder Relations - The company has committed to maintaining its independence, ensuring that key management personnel do not hold positions in other companies controlled by the parent company[113]. - The company will ensure that any business opportunities that may compete with the listed company's main operations will be prioritized for the listed company[123]. - The company has guaranteed that it will not use its controlling shareholder status to harm the interests of minority shareholders[129]. - The commitment to avoid competition includes notifying the company of any business opportunities that may conflict with its main operations[129]. Financial Health - The company's cash and cash equivalents decreased by 354.80%, totaling CNY -96,002,024.72, compared to CNY -21,108,730.70 in the same period last year[54]. - The company's total liabilities decreased to CNY 275,696,615.54 from CNY 316,252,260.07 at the start of the year[189]. - The total owner's equity decreased to CNY 217,341,138.53 from CNY 244,175,673.24 at the beginning of the year[189]. - The company reported a net loss in retained earnings, with undistributed profits at CNY -294,733,910.32 as of June 30, 2022[189]. - The company’s financial report for the first half of 2022 was not audited[185].

证券代码：000638 证券简称：*ST 万方 公告编号：2022-038 万方城镇投资发展股份有限公司 2022 年第一季度报告全文 万方城镇投资发展股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 24,262,961.46 | 30,359,764.25 | -20.08% | | 归属于上市公司股东的净利润（元） | -6,163,241.66 | 15 ...

Financial Performance - The company's operating revenue for 2021 was CNY 327,024,966.35, representing a 194.63% increase compared to CNY 110,993,349.65 in 2020[22] - The net profit attributable to shareholders for 2021 was CNY 62,819,540.74, a significant increase of 468.33% from a loss of CNY 17,055,247.54 in 2020[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 8,016,546.61, improving by 145.95% from a loss of CNY 17,446,291.42 in the previous year[22] - The basic earnings per share for 2021 was CNY 0.20, compared to a loss of CNY 0.06 per share in 2020, marking a 433.33% increase[22] - The diluted earnings per share for 2021 was CNY 0.20, an increase of 433.33% compared to CNY -0.06 in 2020[23] - The weighted average return on equity reached 44.54%, up 58.78% from -14.24% in the previous year[23] - Total assets increased by 10.45% to CNY 560,427,933.31 at the end of 2021, compared to CNY 507,416,635.12 at the end of 2020[23] - Net assets attributable to shareholders rose by 61.52% to CNY 177,058,616.12 from CNY 109,620,523.97 in 2020[23] - The company achieved total revenue of CNY 327,024,966.35 in 2021, representing a year-on-year increase of 194.63%[62] - The net profit attributable to the parent company was CNY 62,819,540.74, a significant increase of 468.33% compared to the previous year[62] - The company's operating costs totaled CNY 229,443,079.95, which is an increase of 186.17% year-on-year[63] Cash Flow and Investments - The net cash flow from operating activities was negative CNY 52,777,081.12, worsening from negative CNY 1,739,421.80 in 2020[22] - The investment activities generated a net cash flow of CNY 65,947,026.35, primarily from the disposal of subsidiary equity[66] - The financing activities resulted in a net cash flow of CNY 83,241,933.12, mainly from loans and investments[67] - The total cash and cash equivalents increased by 96,411,878.55 yuan, reflecting a growth of 759.41% year-over-year[87] - The cash inflow from investment activities surged to 296,061,967.34 yuan, marking a dramatic increase of 2,588.04% compared to 11,014,048.83 yuan in 2020[87] - The cash outflow from operating activities rose to 377,922,350.76 yuan, an increase of 21.83% from 310,204,542.38 yuan in the previous year[86] Business Strategy and Development - The company is positioned to benefit from the ongoing military expansion globally, with increased defense budgets in major countries[32] - The agricultural sector is expected to grow due to favorable government policies and investments in infrastructure, aligning with the company's business strategy[36] - The company aims to leverage its agricultural resources in Jilin Province to enhance local production and contribute to regional development[35] - The biopharmaceutical sector is a key focus for the company, driven by increasing health security demands due to population growth and aging trends in China[37] - The company aims to enhance its competitive edge through the development of innovative vaccines, as the domestic vaccine market is expected to continue its rapid growth[38] - The company is implementing a diversified business strategy, including agriculture, military, biopharmaceuticals, and medical software, to optimize asset allocation and improve overall competitiveness[39] - The company plans to focus on military, agricultural, and bioproducts sectors by divesting from the medical information technology business, with a transaction price of 172.71 million yuan for a 55.30% stake[109] Acquisitions and Partnerships - In 2021, the company completed the acquisition of controlling interest in Zhuding Gongda, entering the military industry and expanding its business portfolio[40] - The company has signed cooperation agreements with China Supply and Marketing Cooperative for 10,000 tons of rice and 20,000 tons of corn[58] - The company has divested its 55.30% stake in Xintong Network to focus on military, agricultural, and bioproducts sectors, completing the transaction and registration[50] - The company is actively pursuing partnerships with various organizations to enhance market share and expand its agricultural business[47] Research and Development - Research and development expenses amounted to CNY 10,748,324.02, with CNY 5,774,849.28 capitalized[64] - The total R&D investment was approximately CNY 5.35 million, accounting for 1.63% of operating revenue, a decrease of 9.51% from the previous year[82] - The number of R&D personnel decreased by 89.84% to 25, significantly impacting the company's R&D capacity[81] - The company plans to continue developing new products, including gradient AL-SI50 aluminum-silicon alloy composite materials, which have already obtained patents[80] - The company acknowledges the high risks associated with the R&D of bioproducts, which require extensive clinical trials and regulatory approvals, leading to uncertainties in product commercialization[128] - The company is committed to improving its R&D project management mechanisms to align research directions with market trends and optimize R&D expenditures[129] Governance and Compliance - The company has established independent financial management and accounting systems, ensuring autonomy from the controlling shareholder[145] - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[138] - The company has implemented a performance evaluation system linking managerial compensation to business performance[141] - The company maintains a transparent information disclosure process, adhering to relevant laws and regulations[143] - The company has conducted shareholder meetings in accordance with legal and regulatory requirements, ensuring equal treatment of all shareholders[136] - The company has a structured governance framework that complies with the guidelines set by the China Securities Regulatory Commission[135] Future Outlook - The company provided guidance for 2022, expecting revenue growth of 10% to 12%[158] - New product launches are anticipated to contribute an additional 200 million in revenue in the next fiscal year[158] - Market expansion plans include entering three new regional markets by the end of 2022[158] - The company plans to increase its marketing budget by 30% to support new product launches and market expansion efforts[158] Employee and Management Structure - The total number of employees at the end of the reporting period is 139, with 45 in technical roles and 43 in production[185] - The company has a total of 4 employees with doctoral degrees and 10 with master's degrees[186] - The company emphasizes long-term talent incentives through its stock option plan to stabilize management and motivate key personnel[187] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.155 million yuan[172] Stock Options and Incentives - The company plans to implement a stock option incentive plan in 2021, granting 7.7 million stock options to 10 initial recipients[187] - The stock options granted to directors and senior management include 1 million shares for each of the directors Su Jianqing and Liu Yu, with an exercise price of 4.88 CNY per share[200]

Financial Performance - The company's operating revenue for Q3 2021 was ¥76,774,866.49, representing a 173.44% increase year-over-year[4] - The net profit attributable to shareholders was a loss of ¥5,491,728.19, a decrease of 558.97% compared to the same period last year[4] - The company achieved a net cash flow from operating activities of -¥62,554,890.97 for the year-to-date, reflecting an 8.64% decrease[4] - The company reported a 125.48% increase in total operating income year-to-date, totaling ¥155,599,882.97, primarily due to revenue from newly acquired subsidiaries[10] - The investment income for the year-to-date was ¥15,714,893.93, a significant increase of 447.23% year-over-year[11] - The company’s basic earnings per share for the reporting period was -¥0.0177, a decrease of 555.56% compared to the previous year[4] - Total operating revenue for Q3 2021 reached ¥155,599,882.97, a significant increase from ¥69,009,397.14 in the same period last year[28] - The net profit for Q3 2021 was ¥5,574,753.71, compared to a net loss of ¥14,349,951.39 in Q3 2020[30] - The company reported an operating profit of ¥6,672,114.66, a turnaround from an operating loss of ¥14,690,715.38 in the previous year[28] - Basic earnings per share for Q3 2021 were ¥0.0156, recovering from a loss of ¥0.0396 per share in the same quarter last year[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥774,506,387.58, an increase of 52.64% from the end of the previous year[4] - As of September 30, 2021, the company's total assets amounted to 774.51 million yuan, an increase from 507.42 million yuan at the end of 2020, representing a growth of approximately 52.5%[26] - The company's total liabilities increased to 542.66 million yuan from 339.02 million yuan, reflecting a rise of about 60.1% year-over-year[27] - Cash and cash equivalents increased to 36.30 million yuan from 31.20 million yuan, showing a growth of approximately 16.5%[25] - Accounts receivable rose significantly to 90.05 million yuan from 48.19 million yuan, indicating an increase of about 86.8%[25] - Inventory levels increased to 242.51 million yuan from 188.39 million yuan, marking a growth of approximately 28.7%[26] - Current liabilities included accounts payable of 22,394,757.13 million and contract liabilities of 56,378,800.74 million[38] Shareholder and Equity Changes - The controlling shareholder changed from Beijing Wanfangyuan Real Estate Development Co., Ltd. to Huide Industrial Co., Ltd. on August 26, 2021, with 26% of voting rights transferred[15][17] - The company’s total equity increased to 231.85 million yuan from 168.39 million yuan, reflecting a growth of approximately 37.7%[27] - The company has a capital reserve of 151,543,126.87 million, contributing to its overall equity structure[39] Financing and Investments - The company plans to sell a 55.30% stake in Chengdu Xintong NetEase Medical Technology Development Co., Ltd. to independent parties, as approved in board meetings on July 1 and October 13, 2021[15][18] - The company approved a total guarantee amount of up to RMB 70 million for 2021 to enhance liquidity and profitability[17] - The company increased the financing guarantee limit for its subsidiary, Jilin Wanfang Maijie Agricultural Industry Development Co., Ltd., to RMB 150 million[18] - The company signed a settlement agreement regarding a debt of RMB 40,068,643.59, with plans for installment repayments[19][20] - The company completed a capital increase for its subsidiary, Zhuding Gongda, raising RMB 10 million, resulting in a dilution of its ownership from 40% to 38.1821%[20] - The company completed the registration procedures for the capital increase of its subsidiary, Wanfang Bai'ao, with a total registered capital increase from 50 million to 74.5 million yuan, resulting in a shareholding reduction from 55% to 36.91%[21] - The company has initiated a capital increase agreement with Wanfang Bai'ao's shareholders, with a total investment of 34 million yuan, enhancing the subsidiary's sustainable operational capacity[22] Cash Flow - Cash flow from operating activities showed a net outflow of ¥62,554,890.97, an improvement from a net outflow of ¥68,468,302.74 in the same period last year[34] - Cash flow from investing activities resulted in a net outflow of ¥13,720,461.66, compared to a net inflow of ¥10,470,155.00 in the previous year[34] - Cash flow from financing activities generated a net inflow of ¥81,371,765.93, significantly higher than the previous year's inflow of ¥1,498,417.99[34] - The company’s cash and cash equivalents at the end of Q3 2021 totaled ¥36,300,946.06, up from ¥6,159,501.07 at the end of Q3 2020[34] - The company received cash inflows from operating activities totaling ¥213,157,663.63, compared to ¥148,411,818.96 in the previous year[33] Other Notable Events - The company has completed the deregistration of its wholly-owned subsidiary, Wanjing Fangtuo, which will not significantly impact overall business development and profitability[23] - The company adopted the new leasing standards effective January 1, 2021, impacting financial reporting[40] - The report for the third quarter was not audited, indicating a need for caution in interpreting the financial data[41]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥78,825,016.48, representing a 92.57% increase compared to ¥40,932,114.01 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥10,321,115.30, a significant turnaround from a loss of ¥11,417,085.12 in the previous year, marking a 190.40% improvement[21]. - The total assets at the end of the reporting period were ¥679,855,620.33, an increase of 33.98% from ¥507,416,635.12 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 8.83%, amounting to ¥119,295,696.83 compared to ¥109,620,523.97 at the end of the previous year[21]. - The basic earnings per share were ¥0.0334, a recovery from a loss of ¥0.0369 per share in the same period last year, reflecting a 190.51% increase[21]. - The weighted average return on net assets was 9.02%, a significant increase of 16.89% from -7.87% in the previous year[21]. - The company reported a total grain production of 36.33 million tons in Jilin Province, with corn production at 27.99 million tons and a yield of 6,616.80 kg/hectare[36]. - The company achieved an agricultural, forestry, animal husbandry, and fishery value-added of 120.48 billion yuan in the province[36]. - The company reported a total revenue of 3,126 million yuan for the first half of 2021, showing a significant increase compared to the previous period[169]. - The net profit attributable to shareholders reached 194.41 million yuan, reflecting a growth of 6% year-on-year[171]. Cash Flow and Financing - The net cash flow from operating activities improved by 43.67%, reaching -¥38,195,209.85, compared to -¥67,807,457.25 in the same period last year[21]. - The company reported a significant increase in financing activities, with cash flow from financing activities reaching ¥29,113,287.25, a 1,220.98% increase from ¥2,203,914.16, mainly due to loans taken by Zhuding Gongda[52]. - The company raised CNY 52,657,097.88 through borrowings, compared to CNY 9,760,000.00 in the previous year, indicating increased financing activity[163]. - The net cash flow from financing activities was CNY 29,113,287.25, a significant increase from CNY 2,203,914.16 in the same period of 2020[163]. - The company raised ¥30,000,000.00 through financing activities, leading to a net cash flow from financing activities of ¥29,500,000.00, compared to a net outflow of -¥2,038,460.95 in the previous year[166]. Investments and Acquisitions - The company acquired a 40% stake in military enterprise Zhuding Gongda, entering the military industry, which focuses on high-silicon aluminum alloys and gradient high-silicon aluminum alloys for advanced electronic packaging materials[29]. - The company is in the process of selling a 55.30% stake in Chengdu Xintong Net Medical Technology Development Co., Ltd. to enhance its financial position[39]. - The company made a significant equity investment of 7,200,000 yuan in a colored alloy materials company, acquiring a 40% stake[66]. - The acquisition of Harbin Zhuding Industrial New Materials Co. is expected to have a positive impact on the company's future financial status and operational results[77]. - The company has initiated a strategic acquisition plan to enhance its competitive edge in the market[171]. Agricultural Operations - The company expanded its agricultural operations through a 60% stake in Wan Fang Mai Jie, focusing on a modern agricultural supply chain and implementing a "trust planting" model to optimize land use[32]. - Wan Fang Mai Jie signed contracts for 143.6 mu (approximately 2154.2 acres) of entrusted planting, aiming to enhance production efficiency and establish a solid foundation for future expansion[33]. - Wan Fang Mai Jie generated 13.83 million yuan in corn trade revenue in the first half of 2021, despite challenges from adverse weather conditions affecting grain quality[34]. - The agricultural sector benefits from favorable government policies aimed at enhancing food security and promoting agricultural modernization, aligning with the company's strategic decisions[35]. - The company is actively expanding its agricultural services through its subsidiary WanFang MaiJie, which focuses on grain processing and sales[78]. Military and Technology Development - The military new materials sector is expected to grow significantly due to increasing demands from defense and military construction, with a favorable long-term outlook driven by domestic policies and technological advancements[31]. - The company has successfully developed and is now mass-producing advanced electronic packaging materials, including high-silicon aluminum alloys, addressing critical issues for military clients[44]. - The high-silicon aluminum alloy materials developed by the company have significant application prospects in military and civilian fields, including aerospace and satellite communications[43]. - The new double-sided gradient silicon-aluminum packaging product can nearly double the integration level of packaging modules without increasing weight, or reduce the volume by nearly half while maintaining the same integration level[44]. Risk Management and Strategic Focus - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[4]. - The company is facing risks from macroeconomic fluctuations and regulatory changes, which could adversely affect its financial performance[80]. - The company aims to enhance its research and development management to align with market trends and reduce the risk of project failures[82]. - The company has identified the need for talent acquisition and market incentives to support its new business ventures and mitigate associated risks[81]. - The company is committed to improving its internal control systems to enhance overall operational efficiency and manage risks in new fields[81]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company held its first extraordinary general meeting on March 10, 2021, with an investor participation rate of 37.95%[85]. - The second extraordinary general meeting on April 22, 2021, had a participation rate of only 0.02%[85]. - The annual general meeting on May 6, 2021, recorded a participation rate of 38.22%[85]. - The company approved the 2021 stock option incentive plan on April 6, 2021, and the plan was further ratified on April 22, 2021[90]. Financial Position and Assets - The company's total liabilities were CNY 485,439,726.64, up from CNY 339,024,570.76, which is an increase of about 43%[146]. - The company's cash and cash equivalents decreased to CNY 10,095,802.06 from CNY 31,204,532.76, a decline of about 68%[144]. - The company has a total of 2,860.7 million yuan in payables to related parties at the end of the reporting period[110]. - The company has a receivable from related parties amounting to 8,249.75 million yuan at the end of the reporting period[110]. - The company has maintained a stable capital structure with no new equity issued during the reporting period[176].